TCL Archive Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent September 30, 2011
TCL Archive Patient Advocacy: Prostate Cancer Agenda Didn’t Include NCI Plans, Lausner Says November 29, 1996
TCL Archive Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products. July 9, 2004